Royal Bank of Canada Has $18.17 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Royal Bank of Canada boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,181,964 shares of the company’s stock after purchasing an additional 4,361 shares during the period. Royal Bank of Canada owned about 0.10% of Teva Pharmaceutical Industries worth $18,167,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Jump Financial LLC lifted its stake in Teva Pharmaceutical Industries by 172.1% in the 1st quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock valued at $20,373,000 after purchasing an additional 838,423 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Teva Pharmaceutical Industries by 5.7% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock valued at $38,487,000 after purchasing an additional 134,705 shares during the last quarter. Financial Sense Advisors Inc. raised its holdings in Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock valued at $6,231,000 after acquiring an additional 157,421 shares during the period. King Wealth Management Group raised its holdings in Teva Pharmaceutical Industries by 1,106.9% in the 1st quarter. King Wealth Management Group now owns 175,000 shares of the company’s stock valued at $2,690,000 after acquiring an additional 160,500 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Teva Pharmaceutical Industries by 804.7% in the 1st quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock valued at $1,037,000 after acquiring an additional 60,016 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TEVA shares. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Buy” and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Up 2.0%

NYSE TEVA opened at $19.69 on Wednesday. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a 50 day moving average of $17.15 and a 200-day moving average of $16.43. The company has a market cap of $22.58 billion, a price-to-earnings ratio of -123.06, a PEG ratio of 1.12 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm’s quarterly revenue was up .3% on a year-over-year basis. During the same period in the previous year, the business earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.